Jakafi 5 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FSQP8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,793
Award facts
- Contract value 100% obligated
- $24,793.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a delivery order valued at $24,793.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi (ruxolitinib) 5 mg tablets in quantities of 60. The award, issued on December 17, 2025, with an ultimate completion date of December 18, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V IDC, designated as contract SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. The vendor's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, oncology treatments, and medical consumables, positioning it as a critical supplier within the federal pharmaceutical supply chain. The company's demonstrated performance on numerous delivery orders prior to this award reflects its capability to fulfill specialized pharmaceutical requirements for Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FSQP8?
SPE2DR26FSQP8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FSQP8 worth?
The government has obligated $24,793 on SPE2DR26FSQP8.
Is contract SPE2DR26FSQP8 an order under another contract?
Yes. SPE2DR26FSQP8 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQP8 competed?
The extent of competition for SPE2DR26FSQP8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award